Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Brand Name :
No Data Available.
Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Dosage Forms & Strengths
Oil, Intramuscular:
100mg/ml (3ml)
Tablet, Oral:
50 mg
Hormone Adjunct Therapy For Transgender Females
25 - 50
mg
Orally
once a day
in combination with other appropriate agents; adjust the dose to suppress serum testosterone levels into the normal range for females.
50 - 200
mg
Orally
once a day
(do not exceed 600 mg/day)
or
300 to 600 mg IM every 1 to 2 weeks or
400 to 700 mg IM once a week
Do not use if hepatic failure, thromboembolic disease, or active pituitary pathology.
200 - 300
mg
Orally
given in 2 to 3 divided doses in a day.
Or
300 mg IM once a week, reduce the dose to 300 mg once every 2 weeks depending on clinical symptoms.
Dose Adjustments
Meningioma: Terminate the cyproterone administration permanently.
Thrombophlebitis/thromboembolism: Discontinue treatment.
Prostate-specific antigen progression: discontinue cyproterone treatment and monitor for withdrawal symptoms.
No safe dosing is established
Refer to adult dosing
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
abiraterone acetate and niraparib
may decrease the diagnostic effect of antiandrogens
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
antiandrogens decrease the efficacy of choline C11
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
antiandrogen may decrease the therapeutic efficacy of Choline C 111
may reduce the effective serum concentration of cyproterone
may reduce the therapeutic efficacy of progestins and vice versa
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may increase the hypertensive effect of hypertension-associated agents
may enhance the serum concentration of HMG-CoA Reductase Inhibitors
they decrease the efficacy of choline C11
Cyproterone works as an antiandrogen by blocking androgen receptors, preventing testosterone and dihydrotestosterone from binding to them. It also suppresses luteinizing hormone secretion, leading to reduced testosterone production and activity in the body.
Frequency not defined:
Acute myocardial infraction
Edema
Hypotension
Phlebitis
Cardiac failure
Pulmonary embolism
Retinal thrombosis
Tachycardia
Vasodepressor syncope
Excessive sweating
Eczema
Erythema nodosum
Exfoliative dermatitis
Loss of body hair
Pruritis
Skin discoloration
Skin rash
Urticaria
Xeroderma
Ascites
Hepatic necrosis
Hypersensitivity reaction
Asthenia
Optic atrophy
Optic neuritis
Visual disturbance
Cough
Dyspnea
Hyperventilation
Pulmonary fibrosis
Fever
Cyproterone can increase your skin’s sensitivity to sunlight, making it more prone to reactions such as rash, itching, redness, discoloration, or even severe sunburn after short periods of sun exposure.
Contraindication
In men, cyproterone acetate should not be used in cases of liver disease, cancer, severe weight loss, chronic depression, advanced diabetes with vascular issues, sickle-cell anemia, or a history of blood clots.
Cautions
Cautions include the potential for breast tenderness, swelling, or discharge; fatigue and general weakness; mood changes including depression; hot flushes or sweating; fluid retention causing swelling; and fluctuations in body weight. Monitoring is advised if these symptoms appear.
Pregnancy consideration: Avoid use in patients who can become pregnant.
Lactation: Cyproterone can be excreted in breast milk, avoid use in lactating females.
Pregnancy category:
Cyproterone is a synthetic 21-carbon steroid with progestogenic and weak glucocorticoid activity. At high doses, it blocks androgen receptors, inhibiting the action of androgens. It has a relatively long half-life of approximately 2 days, contributing to its sustained effect.
Pharmacokinetics
Absorption
Completely absorbed after oral administration.
Distribution
Data not available.
Metabolism
Primarily metabolized in the liver by CYP3A4 to form 15β-hydroxycyproterone acetate, which maintains antiandrogen activity but has reduced progestational effects.
Elimination/Excretion
Around 60% is excreted via bile and 33% through the kidneys.
Half-life: Approximately 38 hours after oral administration and 96 hours following intramuscular injection.
Pharmacodynamics
Cyproterone functions as an antiandrogen by blocking androgen receptors, thereby preventing testosterone and dihydrotestosterone from exerting their effects on target tissues. Additionally, it inhibits the release of luteinizing hormone (LH), leading to a decrease in testosterone production. This dual action contributes to its effectiveness in managing androgen-related conditions.
Cyproterone is typically given daily at a dose of 50 to 100 mg from day 5 to day 15 of the treatment cycle. Due to its slow metabolism, it is started early in the cycle. When combined with ethinyl estradiol, a 50 µg dose of the estrogen is usually added from day 5 to day 26.
Generic Name: Cyproterone
Pronounced: SYE-proe-teh-rone
Why do we use Cyproterone?
Cyproterone is primarily used in the treatment of advanced prostate cancer. It works by blocking androgen receptors and reducing testosterone levels, which helps slow the growth of hormone-sensitive prostate cancer cells. In some cases, it may also be used to manage symptoms like hot flashes during androgen deprivation therapy or to treat conditions related to androgen excess, such as severe acne or hirsutism, though these uses are more common in women.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
